Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending February 2015. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs). Specifically, it details the grant of conditional share awards on February 11, 2015, under the GlaxoSmithKline 2009 Performance Share Plan (PSP) and the 2009 Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed are the share prices used to calculate the awards: an Ordinary Share price of £15.195 (London Stock Exchange) and an ADS price of US$46.25 (New York Stock Exchange), both based on the closing price on February 10, 2015.
Material Changes and Transaction Details
The primary material event is the grant of equity-based compensation to Executive Directors and PDMRs. The awards are subject to a three-year performance period from January 1, 2015, to December 31, 2017. Vesting is contingent upon three equally weighted performance measures:
- Total Shareholder Return (TSR): Relative performance against a comparator group of nine other global pharmaceutical companies. Vesting ranges from 0% (ranked 6th or below) to 100% (ranked 1st-3rd).
- Adjusted Free Cash Flow: Targets to be determined following the completion of a three-part transaction with Novartis, expected in the first half of 2015. Communication of targets is anticipated by the end of July 2015.
- R&D New Product Performance: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at the threshold to 100% for performance exceeding 122% of the threshold.
Executive Directors face an additional two-year vesting period (five years total) for these awards, with forfeiture only occurring in cases of termination for cause.
Guidance, Outlook, and Risks
Management commentary indicates that specific performance targets for Adjusted Free Cash Flow and R&D new products will not be fully disclosed until later in the performance period or upon completion of the Novartis transaction. The filing highlights the risk that awards may lapse entirely if performance thresholds are not met. No specific financial guidance or outlook regarding the company's overall business operations is provided in this document.
Investor Verification Checklist
- Verify the completion date and terms of the three-part transaction with Novartis to understand the basis for the Adjusted Free Cash Flow targets.
- Monitor the disclosure of R&D new product performance targets, which are currently withheld for commercial sensitivity.
- Track GSK's TSR ranking relative to the specified comparator group (AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche Holdings, Sanofi) over the 2015-2017 period.
- Review the specific vesting schedules for Executive Directors, noting the extended five-year holding period.